Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644 1645 1674 1699
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17699868 | METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17928561 | ANTIBODY FORMULATIONS AND USES THEREOF | Non-Final OA | Amgen Inc. |
| 17281896 | METHODS FOR REDUCING AGGREGATION OF BISPECIFIC ANTIBODIES | Non-Final OA | AMGEN INC. |
| 17335680 | Method for the reduction of host cell proteins in affinity chromatography | Final Rejection | Hoffmann-La Roche Inc. |
| 18336889 | COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | Non-Final OA | Bristol-Myers Squibb Company |
| 19190045 | RISANKIZUMAB COMPOSITIONS | Non-Final OA | ABBVIE INC. |
| 19070188 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SYSTEM ATROPHY (MSA) | Non-Final OA | H. Lundbeck A/S |
| 18176844 | THERAPEUTIC ANTIBODY FORMULATION | Non-Final OA | Eli Lilly and Company |
| 18926209 | METHOD OF TREATING PRECLINICIAL ALZHEIMER'S DISEASE | Final Rejection | AC IMMUNE SA |
| 16640914 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18152872 | Pharmaceutical Formulations | Non-Final OA | UCB BIOPHARMA SRL |
| 17738131 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18257600 | CONJUGATED AFLATOXIN B TO PROTECT AGAINST MYCOTOXICOSIS | Non-Final OA | Intervet Inc. |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | Non-Final OA | Omeros Corporation |
| 16634497 | REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS | Non-Final OA | Juno Therapeutics, Inc. |
| 18036546 | STABLE AQUEOUS HIGH CONCENTRATION FORMULATION OF INTEGRIN ANTIBODY | Non-Final OA | DR. REDDY’S LABORATORIES LIMITED |
| 18022069 | SIALYLATED GLYCOPROTEINS | Non-Final OA | Momenta Pharmaceuticals, Inc. |
| 18276394 | METHOD AND COMBINATION FOR TREATING TUMORS | Non-Final OA | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED |
| 18262419 | DUAL BINDING ANTIBODIES, METHODS OF PRODUCING DUAL BINDING ANTIBODIES, AND USES THEREOF | Non-Final OA | Biolojic Design Ltd. |
| 18348722 | LYOPHILIZATION PROCESS AND A TEVERELIX-TFA LYOPHILIZATE OBTAINED THEREBY | Non-Final OA | Antev Limited |
| 17289602 | FORMULATIONS OF MULTISPECIFIC ANTIBODIES BINDING PD-L1 AND CD137 | Non-Final OA | BIONTECH SE |
| 18256422 | PROTEIN-DRUG CONJUGATE AND SITE-SPECIFIC CONJUGATING METHOD | Non-Final OA | NONA BIOSCIENCES (SHANGHAI) CO., LTD. |
| 17802927 | METHODS AND COMPOSITIONS FOR PREVENTING ADSORPTION OF THERAPEUTIC PROTEINS TO DRUG DELIVERY SYSTEM COMPONENTS | Non-Final OA | Aptevo Research and Development LLC |
| 18000851 | ANTIBODY FORMULATION DILUENT | Non-Final OA | IGI Therapeutics SA |
| 18054076 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | Non-Final OA | ImmunoGen, Inc. |
| 17821945 | Use of Pharmaceutical Compositions of a HER2/neu Antibody | Non-Final OA | TERSERA THERAPEUTICS LLC |
| 17807211 | METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT | Non-Final OA | Affimed GmbH |
| 17786094 | STABLE HIGH-CONCENTRATION FORMULATION OF NIMOTUZUMAB ANTIBODY | Final Rejection | Centro de Immunología Molecular |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy